CD20
Recombinant Human Cluster of Differentiation 20
Biological information
CD20 is a transmembrane receptor, specific of normal and malignant B-cells. Indeed, CD20 is involved in development and differentiation of B-cells. It boosts calcium signal indirectly and regulates their cellular signalization. CD20 can be subjected by post-translational modifications (phosphorylation). Moreover, it can be found as a double-barrel dimer. As of today, there is no natural ligand known and its function is still debated. CD20 transmembrane receptor is targeted in various diseases like cancer (non-Hodgkin’s lymphoma and Chronic lymphocytic leukemia’s), multiple sclerosis, or autoimmune disorders. The treatment most used for lymphoid malignancies is the Rituximab, a monoclonal antibody, which induced the clustering of CD20 in lipid raft. Thus, this triggers several immune defense mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).
Product specifications
Chemical data
CD20 is a transmembrane receptor, specific of normal and malignant B-cells. Indeed, CD20 is involved in development and differentiation of B-cells. It boosts calcium signal indirectly and regulates their cellular signalization. CD20 can be subjected by post-translational modifications (phosphorylation). Moreover, it can be found as a double-barrel dimer. As of today, there is no natural ligand known and its function is still debated. CD20 transmembrane receptor is targeted in various diseases like cancer (non-Hodgkin’s lymphoma and Chronic lymphocytic leukemia’s), multiple sclerosis, or autoimmune disorders. The treatment most used for lymphoid malignancies is the Rituximab, a monoclonal antibody, which induced the clustering of CD20 in lipid raft. Thus, this triggers several immune defense mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).